ICONHome   ICONContact us   ICONAdd Favorites
Biochemtek
Search Product
Live Chat E-mail
Pharmacology
ICON Inhibitors
ICON Receptors
ICON Hedgehog Signaling Pathway
ICON Stem Cells & Wnt
ICON Signal Transduction
 　 More +
Research Area
ICON Cancer
ICON Antivirus
ICON Cardiovascular System
ICON Endocrinology
ICON Neuroscience
 　 More +
Product Type
ICON Natural Products
ICON Peptides
ICON Prostaglandins
ICON Vitamin D series compounds
ICON Toxins
 　 More +
Browse Alphabetically by Name
ALL A B C D E F
G H I J K L M
N O P Q R S T
U V W X Y Z Others
 
ICONCL2480 ABT-869(Linifanib) (796967-16-3)
 
 
Catalog No.: CL2480
CAS No.: 796967-16-3
Synonym: Linifanib,AL-39324,RG3635
Chemical Name:

N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea

Molecular Formula: C21H18FN5O
Molecular Weight: 375.41
 
Technical Data:
Appearance: White to gray powder
Solubility: Soluble in DMSO
Purity: >99%
Storage: at -20℃ 2 years
Original QC Data:
Shipping Conditions: Ambient Temp.
 
Price and Availability of ABT-869(Linifanib):

Size

Price

Stock

25 mg 

USD 166

In stock 

50 mg 

USD 288

In stock 

100 mg 

USD 488

In stock 

Contact us for competitive discounts on bulk quantities
 
Biological Activity:
ABT-869 is multi-targeted in that it is a potent inhibitor of all members of the VEGF and PDGF receptor families (e.g., KDR IC50 value of 4 nM), but has much less activity (IC50 values >1 µM) against unrelated receptor tyrosine kinases, soluble tyrosine kinases or serine/threonine kinases. The kinase inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 values of 2, 4 and 7 nM for PDGFRß, KDR and CSF-1R, respectively) and VEGF-stimulated proliferation (0.2 nM IC50 for human endothelial cells).
 
References:

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Shankar DB,et al Blood. 2007 Apr 15;109(8):3400-8.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Albert DH, Mol Cancer Ther. 2006 Apr;5(4):995-1006.

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Zhou J,Leuk Res. 2008 Jul;32(7):1091-100. Epub 2007 Dec 26

 
View Related Products by Target:
Nilotinib(AMN 107)
NVP-TAE684-TAE 684
Motesanib(AMG706)
Imatinib mesylate(STI-571)
BIBW 2992(Afatinib)
Dovitinib lactate hydrate ( TKI258 lactate hydrate; CHIR-258 lactate hydrate)
Pelitinib(EKB-569)
PF 2341066(Crizotinib)
BIBF1120(Vargatef)
CHIR-258(Dovitinib,TKI258)
Brivanib alaninate(BMS-582664)
Lapatinib Ditosylate (GW-572016)
 
 

Keywords: Buy ABT-869(Linifanib) | ABT-869(Linifanib) Supplier | Purchase ABT-869(Linifanib) | ABT-869(Linifanib) Cost | ABT-869(Linifanib)  Manufacturer | Order ABT-869(Linifanib) | ABT-869(Linifanib) Distributor | ABT-869(Linifanib) Structure, Chembest

Buy 796967-16-3| 796967-16-3 Supplier | Purchase 796967-16-3 | 796967-16-3 Cost | 796967-16-3 Manufacturer | Order 796967-16-3 | 796967-16-3 Distributor | 796967-16-3 Structure, Chembest  
Products are for research use only. Not for human use. We do not sell to patients.
Copyright © 2010-2025 Chembest Research Laboratories. All Rights Reserved
E-mail:sales@biochembest.com